CALC Positive Sentiment
CalciMedica Announces Upcoming Symposium at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology Meeting
Thursday, June 12, 2025 BiopharmaWatch Research 1 min read Key Takeaway: CalciMedica Inc. announced its participation in the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology meeting, where it will present a symposium on 'Auxora for the Treatment of AKI'. The event will feature several presentations by leading experts discussing CRAC channels and their role in AKI. Webcasts of the presentations will be available on CalciMedica's investor relations website.
Full Press Release Details
LA JOLLA, Calif.,June 12, 2025/PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced an upcoming symposium entitled "Auxora for the Treatment of AKI" at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology meeting being heldJune 24-26in Vicenza,Italy.
Details for the oral presentations to be presented during the symposium are as follows:
Presentation Title:Overview of Calcium Release-Activated Calcium (CRAC) ChannelsPresenter:Sudarshan Hebbar, M.D., Chief Medical Officer of CalciMedicaDate and Time:Tuesday, June 24, 1:45-2:00 p.m. CEST
Presentation Title:The Role of IL-17 in the Pathophysiology of AKIPresenter:Javier Neyra, M.D., Associate Professor of Medicine and Associate Director of the Nephrology Research & Training Center atUniversity of Alabama at BirminghamDate and Time:Tuesday, June 24, 2:00-2:20 p.m. CEST
Presentation Title:KOURAGE (NCT06374797)Presenter:Lakhmir Chawla, M.D., Clinical Professor of Medicine atUniversity of California San Diego, Chief Medical Officer at ExThera Medical, and Chair of the KOURAGE Steering CommitteeDate and Time:Tuesday, June 24, 2:20-2:35 p.m. CEST
Webcasts of the presentations will be available following the sessions on the Medical Events & Presentations section of CalciMedica's IR website at
https://ir.calcimedica.com/news-events/medical-events-publications.
About CalciMedicaCalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate Auxora™ has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials and been well-tolerated in over 350 critically ill patients dosed. CalciMedica has announced data for a Phase2btrial (called CARPO –NCT04681066) in patients with acute pancreatitis (AP) and accompanying systemic inflammatory response syndrome (SIRS) and for a Phase 2 trial (called CARDEA –NCT04345614) in patients with COVID pneumonia. The Company is currently conducting a Phase 2 trial (called KOURAGE –NCT06374797) in patients with acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF). For more information, please visitwww.calcimedica.com.
Contact InformationArgot Partnersemail protected 600-1902